FDA Peptide Review Could Ease Access, but Safety Questions Remain
Federal advisers have opened the door to temporary access for several unapproved peptide products, even as FDA warnings continue to stress that compounded versions are not reviewed for safety, effectiveness or quality.
FDA mifepristone review stretches into 2027 as debate continues
The FDA says its ongoing safety review of mifepristone will continue into next year, keeping one of the nation’s most closely watched drug-policy fights in motion.